Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Immunology

HLA Class I Antigen and Transporter Associated with Antigen Processing (TAP1 and TAP2) Down-Regulation in High-Grade Primary Breast Carcinoma Lesions

Marco Vitale, Rita Rezzani, Luigi Rodella, Giorgio Zauli, Piergiovanni Grigolato, Moris Cadei, Daniel J. Hicklin and Soldano Ferrone
Marco Vitale
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rita Rezzani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luigi Rodella
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giorgio Zauli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piergiovanni Grigolato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moris Cadei
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel J. Hicklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soldano Ferrone
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published February 1998
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Five specimens of normal mammary tissue and 53 primary breast carcinoma lesions were tested for expression of HLA antigens and components of the antigen-processing machinery by immunohistochemical staining. The expression of transporter associated with antigen processing (TAP) 1, TAP2, and HLA class I antigens in breast carcinoma lesions was significantly associated with tumor grading. Like normal mammary tissue, the 16 low-grade (G1) breast carcinoma lesions showed strong staining for TAP1, TAP2, and HLA class I antigens. In contrast, only 12 (32%) of 37 high-grade (G2 and G3) breast carcinoma lesions displayed the normal staining pattern. In 14 (38%) of 37 high-grade lesions, HLA class I antigen down-regulation was observed without loss of low molecular mass polypeptide and/or TAP staining. Congruent down-regulation of HLA class I antigen and TAP1 or TAP2 was found in 8 (22%) of 37 high-grade lesions. Complete loss of HLA class I antigens, TAP1, and TAP2 was observed in 3 (8%) of 37 high-grade lesions. No lesion was negative for TAP1 and/or TAP2 staining while positive for HLA class I antigen staining. These data demonstrate an association of HLA class I antigen and TAP down-regulation with tumor progression in breast carcinoma. This association suggests that loss of HLA and/or TAP may represent an escape from the host's immune pressure or may reflect the accumulation of abnormalities associated with neoplastic progression. This accumulation of defects in antigen processing and presentation may in turn be responsible for reduced recognition of malignant cells by putative clinically relevant tumor-specific T cells.

Footnotes

  • ↵1 Supported in part by USPHS Grant CA67108 awarded by the National Cancer Institute, Department of Health and Human Servies, by Istituto Superiore della Sanita Progetto Sangue and by Associazione Italiana per la Ricerca sul Cancro grants.

  • ↵2 To whom requests for reprints should be addressed, at Department of Microbiology and Immunology, New York Medical College, Valhalla, NY 10595. Phone: (914) 594-4175; Fax: (914) 594-4176.

  • Received November 10, 1997.
  • Accepted January 5, 1998.
  • ©1998 American Association for Cancer Research.
PreviousNext
Back to top
February 1998
Volume 58, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
HLA Class I Antigen and Transporter Associated with Antigen Processing (TAP1 and TAP2) Down-Regulation in High-Grade Primary Breast Carcinoma Lesions
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
HLA Class I Antigen and Transporter Associated with Antigen Processing (TAP1 and TAP2) Down-Regulation in High-Grade Primary Breast Carcinoma Lesions
Marco Vitale, Rita Rezzani, Luigi Rodella, Giorgio Zauli, Piergiovanni Grigolato, Moris Cadei, Daniel J. Hicklin and Soldano Ferrone
Cancer Res February 15 1998 (58) (4) 737-742;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
HLA Class I Antigen and Transporter Associated with Antigen Processing (TAP1 and TAP2) Down-Regulation in High-Grade Primary Breast Carcinoma Lesions
Marco Vitale, Rita Rezzani, Luigi Rodella, Giorgio Zauli, Piergiovanni Grigolato, Moris Cadei, Daniel J. Hicklin and Soldano Ferrone
Cancer Res February 15 1998 (58) (4) 737-742;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract 6655: Tumor microenvironment evaluation and tumor intrinsic genomic features predict anti-PD-1 response of metastatic gastric cancer: Results from phase II clinical trial and multi-omics data
  • Abstract 6599: Screening and characterization of AlloCAR T targeting DLL3 for the treatment of small cell lung cancer
  • Abstract 6673: B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity
Show more Immunology

Articles

  • Core-Binding Factor: A Central Player in Hematopoiesis and Leukemia
  • Insights from Bcl-2 and Myc: Malignancy Involves Abrogation of Apoptosis as well as Sustained Proliferation
  • The Effect of Chromosomal Translocations in Acute Leukemias: The LMO2 Paradigm in Transcription and Development
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement